New depression pill LV232 enters Mid-Stage trial
NCT ID NCT06828887
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tests an experimental drug called LV232 for people with major depressive disorder. About 400 adults aged 18 to 65 will receive either LV232 or a placebo for 8 weeks to see if it reduces depression symptoms. The goal is to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Mental Health Center Ethics Committee
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.